Nosefrin - Instructions For Use, Price, Reviews, Spray Analogues

Table of contents:

Nosefrin - Instructions For Use, Price, Reviews, Spray Analogues
Nosefrin - Instructions For Use, Price, Reviews, Spray Analogues

Video: Nosefrin - Instructions For Use, Price, Reviews, Spray Analogues

Video: Nosefrin - Instructions For Use, Price, Reviews, Spray Analogues
Video: How To Use Nasal Spray | How To Use Nasal Spray Properly | Nasal Spray Technique (2018) 2023, March


Nosephrine: instructions for use and reviews

  1. 1. Release form and composition
  2. 2. Pharmacological properties
  3. 3. Indications for use
  4. 4. Contraindications
  5. 5. Method of application and dosage
  6. 6. Side effects
  7. 7. Overdose
  8. 8. Special instructions
  9. 9. Application during pregnancy and lactation
  1. 10. Use in childhood
  2. 11. Use in the elderly
  3. 12. Drug interactions
  4. 13. Analogs
  5. 14. Terms and conditions of storage
  6. 15. Terms of dispensing from pharmacies
  7. 16. Reviews
  8. 17. Price in pharmacies

Latin name: Nozefrin

ATX code: R01AD09

Active ingredient: mometasone (mometasone)

Manufacturer: VERTEX, JSC (Russia)

Description and photo updated: 22.11.2018

Prices in pharmacies: from 395 rubles.


Dosed nasal spray Nosephrine
Dosed nasal spray Nosephrine

Nosephrin is a topical glucocorticosteroid (GCS).

Release form and composition

The dosage form of Nosefrin is a dosed nasal spray: a suspension of a white or almost white gel-like structure, which, when shaken, turns into a liquid [18 g (120 doses) in plastic bottles with a dispenser and a cap, in a cardboard box 1 bottle].

Composition of 1 dose of the drug:

  • active substance: mometasone furoate - 50 mcg;
  • auxiliary components: sodium citrate dihydrate, glycerol, sodium carboxymethylcellulose, microcrystalline cellulose, benzalkonium chloride (50% solution), citric acid monohydrate, polysorbate 80, purified water.

Pharmacological properties

Nosephrine is a drug that has antiallergic, anti-inflammatory, glucocorticoid and anti-congestive effect.


Mometasone is a topical glucocorticosteroid. When used in doses that are not capable of causing systemic effects, it has antiallergic and anti-inflammatory effect. Inhibits the release of inflammatory mediators. It also reduces inflammation by reducing the formation of chemotaxis substance, influencing late allergy reactions. Increases the production of lipomodulin, an inhibitor of phospholipase A, as a result of which the release of arachidonic acid decreases and, as a result, the synthesis of its metabolic products - prostaglandin and cyclic endoperoxides is suppressed. Prevents marginal accumulation of neutrophils, which inhibits the migration of macrophages, reduces the production of lymphokines, inflammatory exudate, processes of infiltration and granulation.

Due to inhibition of the production of metabolites of arachidonic acid and a decrease in the release of inflammatory mediators from mast cells, mometasone stops the development of an immediate allergic reaction.

In studies with provocative tests, when antigens were applied to the nasal mucosa, a pronounced anti-inflammatory effect of mometasone was found both in the early and in the late stages of the allergic reaction. This was confirmed by a decrease (compared with placebo) in eosinophil activity and histamine levels, and a decrease (compared to baseline) in the number of neutrophils, eosinophils, and epithelial cell adhesion proteins.


After intranasal administration of Nosephrine, the systemic bioavailability of mometasone is less than 1% (the sensitivity of the determination method is 0.25 pg / ml).

In this dosage form, the drug is very poorly absorbed in the gastrointestinal tract. The small amount of suspension that can enter the digestive system after being introduced into the nasal cavity undergoes active primary metabolism even before excretion with bile and urine.

Indications for use

  • polyposis of the nose with impaired sense of smell and nasal breathing in adults;
  • acute rhinosinusitis with mild to moderate symptoms without signs of severe concomitant bacterial infection in adults and children over 12 years old;
  • acute sinusitis, exacerbation of chronic sinusitis in adults (including the elderly) and children over 12 years of age (as part of complex therapy);
  • year-round and seasonal allergic rhinitis in adults and children from 2 years of age;
  • preventive therapy (2–4 weeks before the expected start of the dusting season) of moderate and severe seasonal allergic rhinitis in adults and children over 12 years old.



  • recent surgery or nasal trauma with damage to the nasal mucosa (until the wound is completely healed);
  • children under 2 years of age - with seasonal and year-round allergic rhinitis, up to 12 years - with exacerbation of chronic sinusitis and acute sinusitis, up to 18 years - with polyposis;
  • hypersensitivity to any component of the drug.

Relative (Nosephrine should be used with caution):

  • untreated local infection involving the nasal mucosa in the process;
  • untreated systemic viral, bacterial, fungal infection, or Herpes simplex infection with eye damage;
  • active or latent tuberculosis infection of the respiratory tract;
  • long-term therapy with systemic GCS;
  • the period of pregnancy and lactation.

Instructions for the use of Nosephrin: method and dosage

Nosephrine is administered intranasally. The bottle is equipped with a special dispensing nozzle for easy suspension injection. When injecting the drug, it is necessary to tilt your head and inject a spray into each nasal passage at the dose prescribed by your doctor.

Before using the drug for the first time, you should calibrate it: press the dispensing nozzle 6-7 times. This makes it possible to provide in the future a stereotyped delivery of 50 μg of mometasone (0.1 g of suspension). Re-calibration must be performed if Nosephrine has not been used for 14 days or more.

Shake the bottle vigorously before each use.

Seasonal and perennial allergic rhinitis

For children over 12 years old and adults, including the elderly, for preventive and therapeutic purposes, it is recommended to do 2 injections (100 mcg) in each nasal passage once a day. The total daily dose is 200 mcg. After achieving the required therapeutic effect, the dose can be reduced to 1 injection (50 mcg) in each nostril 1 time per day. If, when using Nosephrin in a daily dose of 200 mcg, it is not possible to reduce the symptoms of the disease, it is possible to increase it to 400 mcg - 4 injections (200 mcg) in each nasal passage once a day. After improvement of the condition, it is recommended to reduce the dose.

Children from 2 to 12 years old are usually prescribed 1 injection into each nasal passage once a day. Children may need adult help when using the drug.

The clinical manifestations of the action of mometasone are usually noted as early as 12 hours after the first intranasal administration of Nosephrine.

Acute sinusitis and exacerbation of chronic sinusitis (as part of complex therapy)

Children from 12 years old and adults are usually prescribed 2 injections into each nasal passage 2 times a day. The total daily dose is 400 mcg. If, when using this daily dose, it is not possible to achieve a decrease in symptoms, it is increased to 800 μg - 4 injections into each nostril 2 times a day. After improvement of the condition, the dose of Nosephrin is recommended to be reduced.

Acute rhinosinusitis without evidence of severe bacterial infection

Children from 12 years old and adults are prescribed 2 injections into each nasal passage 2 times a day. The total daily dose is 400 mcg. If the condition worsens during therapy, a doctor's consultation is required.

Polyposis of the nose

Adults are prescribed 2 injections into each nostril 2 times a day. The total daily dose of mometasone is 400 mcg. After it is possible to achieve a decrease in the symptoms of the disease, it is recommended to reduce the daily dose to 200 mcg - 2 injections into each nasal passage once a day.

Side effects

Adults and adolescents may experience the following side effects: irritation of the nasal mucosa, burning sensation in the nose, ulceration of the nasal mucosa, nosebleeds (obvious bleeding or discharge of blood-stained mucus / blood clots), sensation of irritation of the pharyngeal mucosa, pharyngitis, upper infections respiratory tract, headache. The resulting nosebleeds are usually moderate and stop on their own, the frequency of their development is somewhat higher than with placebo (5%), but equal or even less than with other intranasal corticosteroids used as active control (in some drugs, the incidence of nosebleeds reached 15%). The incidence of other side effects is comparable to that with placebo.

During the period of treatment with the drug, children may experience: headache, sneezing, irritation in the nose, nosebleeds. Their incidence is comparable to that of a placebo.

Other possible side effects of Nosephrine:

  • rarely: immediate hypersensitivity reactions, including shortness of breath, bronchospasm;
  • very rare: disturbances in taste and smell, angioedema, anaphylaxis, perforation of the nasal septum, increased intraocular pressure.

With prolonged use of Nosephrin in high doses, like other nasal corticosteroids, systemic side effects may develop. Potential systemic effects include: glaucoma, cataracts, adrenal suppression, characteristic features of cushingoid, Cushing's syndrome, growth retardation in children and adolescents; less often - a number of behavioral and psychological effects, including anxiety, sleep disturbance, psychomotor hyperactivity, aggression, depression (especially in children).


With prolonged use of Nosephrin in high doses or the simultaneous use of other GCS, it is possible to suppress the function of the hypothalamic-pituitary-adrenal system.

Mometasone is characterized by low systemic bioavailability when administered intranasally, therefore it is unlikely that overdose (whether accidental or deliberate) will require any specialized measures other than monitoring. If necessary, symptomatic therapy is performed. In the future, it is possible to resume treatment with Nosefrin at the recommended dose.

special instructions

Nosephrine is not intended for ophthalmic use.

In the case of long-term treatment (several months or more), it is necessary to undergo periodic examinations with a doctor in order to timely identify possible changes in the nasal mucosa.

Patients receiving the drug for a long time should be under constant supervision. The likelihood of developing systemic side effects with the use of Nosephrine is lower than with the use of systemic corticosteroids, and may differ in different patients, as well as depending on the type of corticosteroids. Nevertheless, prolonged use of high-dose nasal corticosteroids can lead to systemic adverse events.

If a local fungal infection of the nose / pharynx develops, it may be necessary to discontinue mometasone and carry out appropriate therapy. An indication for the cancellation of Nosephrine is also irritation of the mucous membrane of the nasal cavity / pharynx, which persists for a long time.

Patients who are transferred to Nosephrin spray from systemic GCS used for a long time should be under special supervision. Cancellation of systemic corticosteroids in such patients can lead to the development of adrenal insufficiency, which may take several months to recover. When signs of adrenal insufficiency appear, it is necessary to resume the use of systemic GCS and take other necessary measures.

In some patients, when switching to Nosephrine from systemic corticosteroids, symptoms of their withdrawal occur, including a feeling of fatigue, depression, pain in muscles and / or joints. Such patients need to be convinced of the advisability of using Nosephrin spray. Also, during the transition, the development of allergic diseases (for example, eczema or allergic conjunctivitis), which were previously masked by systemic GCS, is possible.

Patients receiving GCS have a potential for a decrease in immune reactivity, therefore they should be warned that they are at increased risk of infection in case of contact with a patient with certain infectious diseases (for example, measles or chickenpox) and should consult a doctor if such contact occurs …

In children receiving long-term mometasone, it is necessary to monitor growth. If it slows down, you should revise the therapy regimen and reduce the dose of Nosephrine to the minimum effective (one that will control the symptoms of the disease). Consultation of a pediatrician is required.

When using the drug in higher doses than recommended, clinically significant suppression of adrenal function is possible.

Immediate medical advice is required if signs of severe bacterial infection develop, for example, when fever, swelling in the orbital or periorbital region, persistent and sharp toothache, or pain on one side of the face occurs.

In the course of clinical observations of the use of mometasone in the form of a nasal spray for 12 months, signs of atrophy of the nasal mucosa were not detected.

The efficacy and safety of Nosephrin has not been studied for polyps associated with cystic fibrosis, unilateral polyps and polyps that completely cover the nasal cavity.

Unilateral polyps of irregular shape or bleeding polyps should be examined additionally before the appointment of Nosephrin.

Influence on the ability to drive vehicles and complex mechanisms

No information available.

Application during pregnancy and lactation

Studies of the effect of mometasone in pregnant and lactating women have not been conducted. During these periods of a woman's life, Nosephrine, like other nasal corticosteroids, can be used only in cases where the intended benefits are higher than the potential risks.

Newborns whose mothers received Nosephrine therapy during pregnancy should be carefully examined to identify possible adrenal hypofunction.

Pediatric use

Due to the lack of data on the safety of use, Nosephrin is not prescribed to children under 2 years of age for the treatment of seasonal and year-round allergic rhinitis, under 12 years of age - acute sinusitis and exacerbation of chronic, up to 18 years - polyposis.

Use in the elderly

According to the instructions, Nosephrine is used in old age according to indications. No dose adjustment is required.

Drug interactions

Good tolerance and lack of interaction reactions were noted with the simultaneous use of mometasone in combination with loratadine.

Interaction studies of Nosephrine with other drugs have not been conducted.


Nasal sprays Nasonex, Momat Rino, Dezrinit, Galazolin Allergo are analogues of Nosephrin.

Terms and conditions of storage

Keep out of reach of children at temperatures up to 25 ° C. Avoid freezing.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Nosephrine

According to the overwhelming majority of reviews, Nosephrin is an effective antiallergic drug that can be used for a long time, and which is packaged in convenient bottles equipped with a dispenser spray. This tool is a domestic analogue of imported Nazonex, while, according to patients, it is in no way inferior to it in effectiveness, but it costs much less.

Price for Nosephrine in pharmacies

The price for Nosefrin is approximately 367–418 rubles per bottle (120 doses).

Nosephrine: prices in online pharmacies

Drug name



Nosephrine 50 μg / dose 120 doses nasal spray dosed 18 g 1 pc.

395 RUB


Nasal nasal spray. dosage. 50 mcg / dose 120 doses vial. with dosage device 18g

RUB 500


Anna Kozlova
Anna Kozlova

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!

Popular by topic